Q2 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript

Aug 7, 2025 / 12:30 PM GMT

Release Date Price: €118 (+6.31%)

Transcript 10-Q8-K

Key Points

Positve

Royalty revenue grew 57% year-over-year, showcasing strong performance across Ligand Pharmaceuticals Inc (LGND)'s portfolio.
The company ended the quarter with a robust balance sheet, including approximately $450 million in deployable capital.
Ligand Pharmaceuticals Inc (LGND) completed a strategic merger of Pilthos with Channel Therapeutics, enhancing its business development activities.
The company partnered with Medtronic and Orchestra BioMed to support the development of promising cardiovascular therapies, receiving FDA breakthrough device designations.
Merck's planned $10 billion acquisition of Verona is expected to accelerate the launch trajectory of 02 there, where Ligand Pharmaceuticals Inc (LGND) receives a 3% royalty on worldwide net sales.

Negative

Operating expenses increased due to headcount growth and investments in the Pelthos business, impacting overall profitability.
The tax rate is higher due to increased revenue from foreign operations, affecting net income.
Share count dilution is expected to rise as the stock price increases, potentially impacting earnings per share.
Despite strong product performance, the company is not seeing as much operating leverage as expected, limiting bottom-line growth.
The launch of new products like Zelsumi is anticipated to be challenging, with modest expectations for initial sales traction.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LGND.OQ - Ligand Pharmaceuticals Inc
Q2 2025 Ligand Pharmaceuticals Inc Earnings Call
Aug 07, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the ligand 2nd quarter, 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press the one again.

For operator assistance throughout the call, please press 0. And finally, I would like to advise all participants that this call is being recorded.

Thank you.

I'd now like to welcome Melanie Herman, the executive director of investor relations, to begin the conference. Melanie, over to you.

--

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.